Cash falls to $1.9m as operating burn widens to $6.8m

Operating cash outflow grew to $6.8m from $4.4m, and the cash balance fell to $1.9m from $3.4m. Gross borrowings were extinguished from a nominal $10,762 balance. The PBT-versus-NPAT divergence (-74.3pp) reflects the income tax line moving from a credit in FY21 to an expense in FY22, shifting the effective tax rate from -28.5% to -15.4%. Total equity declined to $24.2m from $28.8m.

• With $1.9m of cash and $6.8m of annual operating cash outflow, the business has only a few months of cash at the current burn rate before fresh capital is required. Capex was scaled back sharply to $0.4m from $1.4m (capex/revenue of 61.9% versus 310.9%), but the reduction is nowhere near enough to bridge the operating gap.

• The tax line is distorting the NPAT read. PBT loss widened by 21.2%; NPAT loss widened by 95.5%. The cleaner operating measure is PBT this year because the deferred-tax credit that flattered FY21 has reversed into a tax expense, producing most of the divergence. Operating performance worsened, but not at the magnitude the headline NPAT figure suggests.

• First commercial revenue is a milestone, not yet a business. $0.6m of revenue against a $7.5m pre-tax loss means commercialization is at its earliest stage. The release points to GMP supply contracting and sales/marketing relationships as forward foundations, but the scale of revenue against the cost base means investors are still underwriting a pre-revenue business model.

The half-year shape was unusual: HY22 revenue of $0.360m implies second-half revenue of only $0.286m, suggesting the first-half pace did not sustain. The second-half NPAT loss accelerated to roughly $6.2m from $2.5m in H1, partly because the tax-line reversal landed in H2. Second-half operating cash outflow of $3.1m was modestly better than H1's $3.7m. The release describes the result as in line with company expectations, but supplies no revenue trajectory or breakeven shape the market can underwrite for FY23.

Capex intensity fell sharply (capex down 71.5%), but operating cash outflow grew because the underlying cost base is running well ahead of revenue. Free cash flow before lease payments deteriorated to -$7.2m from -$5.8m, broadly in line with the widening operating loss.

The $0.6m of first product revenue is a step in commercial validation, but at this scale it does not yet test unit economics, channel scale, or recurring demand. The balance-sheet leverage label looks technically stronger because debt was extinguished and net debt is negative, but that reflects the cash pile rather than operating improvement, and the equity buffer is being consumed at roughly $4.6m per year on a comprehensive-income basis. The tax credit that softened FY21 NPAT is not repeating, which removes a non-cash flatter from future comparisons.

This briefing cannot assess the probability of regulatory approvals, distribution-partner conversion, or product volume forecasts in the company's target export markets.